Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d. in asthma patients: a 12-week pilot study

Terzano, Claudio; Oriolo, Francesca

doi:10.29328/journal.jprr.1001004

Cited by 1 publication

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant improvements in asthma control and nocturnal symptoms, in addition to improved stability in lung function, were seen with BMP/F 33 . Mean FEV 1 in the BMP/F group was found to be 78% at third visit and 79.1% at the final assessment compared with 74.5% and 75.8% in the FF/VIL group 33 , thus highlighting the importance of more robust head to head studies comparing different combination inhalers at equivalent commercially available doses.…”

Section: Clinical Research Studiesmentioning

confidence: 94%

See 1 more Smart Citation

Fluticasone Furoate: A Once Daily Preparation in Patients with Persistent Asthma

Lilburn¹,

Ainge‐Allen²,

Thomas³

2019

J Lung Health Dis

View full text Add to dashboard Cite

Asthma affects approximately 240 million people worldwide. It is characterised by an allergic pattern of smooth muscle constriction and airway inflammation, and if chronic, the inflammation can lead to structural changes and fixed airflow obstruction. Bronchodilators relieve the bronchoconstriction, while inhaled corticosteroids reduce the airway inflammation. This paper reviews fluticasone furoate (FF), a novel inhaled corticosteroid with 24-hour duration of action. It is a synthetic fluorinated corticosteroid with agonist activity at the glucocorticoid receptor (GRE). It is reported to have a fast association and slow dissociation from the GRE compared to other ICSs. FF has been found to have a greater lung retention time than all other ICS preparations which may contribute to the extended duration of anti-inflammatory action. FF has extensive first pass hepatic metabolism resulting in a low gastrointestinal bioavailability which is consistent with the findings for other ICS preparations. FF, however, will pass from the lung into the systemic circulation and therefore an adverse profile similar to all ICS is likely, but long term data are needed.FF has demonstrated treatment efficacy for asthma between 100μg and 200μg alone, but in combination with the long-acting beta agonist, vilanterol (FF/VIL 200μg/50μg OD) there were further improvements in lung function relative to monotherapy. There is an increased risk of pneumonia identified in patients with airways disease in associated with ICS preparations and surveillance will be required to determine if this also applies to FF. Once daily therapy, such as FF, may improve compliance and could hopefully be translated into further improvements in asthma-related outcomes.

show abstract

Section: Clinical Research Studiesmentioning

confidence: 94%

“…Of interest, an observational study performed in 40 patients used a slightly lower dose of FF/VIL at 92/22μg OD compared with BMP/formoterol (F) 100/6μg BD 33 . Significant improvements in asthma control and nocturnal symptoms, in addition to improved stability in lung function, were seen with BMP/F 33 .…”

Section: Clinical Research Studiesmentioning

confidence: 99%